Cargando…

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys’ sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose reabsorption by SGLT2. Patients with type 2 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreea, Munteanu Madalina, Surabhi, Swarnkar, Razvan-Ionut, Popescu, Lucia, Ciobotaru, Camelia, Nicolae, Emil, Tufanoiu, Tiberiu, Nanea Ioan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143699/ https://www.ncbi.nlm.nih.gov/pubmed/37109700 http://dx.doi.org/10.3390/medicina59040742

Ejemplares similares

Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)
por: Adam, Cristina Andreea, et al.
Publicado: (2022)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2020)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
por: Koutentakis, Michail, et al.
Publicado: (2023)

Conformational Dynamics of hSGLT1 during Na(+)/Glucose Cotransport
por: Loo, Donald D.F., et al.
Publicado: (2006)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
por: Nakano, Dan, et al.
Publicado: (2022)

Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous
por: Dan Gheorghe, Andrei Cristian, et al.
Publicado: (2019)

Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
por: Sano, Motoaki
Publicado: (2020)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?
por: Ujjawal, Aditi, et al.
Publicado: (2022)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Particular etiology in a case of peripheral tetraparesis
por: Gheorghe, Gabriela S., et al.
Publicado: (2019)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018)

Active site voltage clamp fluorometry of the sodium glucose cotransporter hSGLT1
por: Gorraitz, Edurne, et al.
Publicado: (2017)

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism
por: Gheorghe, Andrei Cristian Dan, et al.
Publicado: (2020)

Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus
por: Takebayashi, Kohzo, et al.
Publicado: (2017)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
por: Choi, Chang-Ik
Publicado: (2016)

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
por: Liu, Zhenghong, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management
por: Fatima, Aroob, et al.
Publicado: (2023)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

Particular evolution in a 72-year-old diabetic patient with acute coronary syndrome
por: Gheorghe, Gabriela S, et al.
Publicado: (2018)

Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
por: Kaneto, Hideaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djt8ippb1fe33edjksmn2olj27